GEN Exclusives

More »

GEN News Highlights

Back to Item »

Karyopharm Raises $10M to Expand Planned Phase I Trials with Anticancer SINE Candidates

Company’s therapeutic approach is based on blocking Crm1 protein involved in export of key proteins from the nucleus.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?